|
|
|
Hair Loss Study Abstract: Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
|
Title
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
Author
Diamanti-Kandarakis E; Mitrakou A; Hennes MM; Platanissiotis D; Kaklas N; Spina J;
Georgiadou E; Hoffmann RG; Kissebah AH; Raptis S
Address
General Hospital, Athens, Greece.
Source
Metabolism, 44: 4, 1995 Apr, 525-31
Abstract
Polycystic ovary (PCO) syndrome is strongly associated with insulin resistance and the
accompanying adverse metabolic profile. To distinguish the mechanisms of this association,
we determined the interactions of PCO with obesity and the influence of ameliorating
direct androgenic actions via short-term treatment with the antiandrogen flutamide.
Insulin sensitivity was determined by the hyperinsulinemic euglycemic clamp in groups of
lean and obese PCO women and weight-matched controls. Compared with control values,
insulin-mediated glucose utilization in PCO women was significantly lower in lean (1.96
+/- 0.17 v 1.24 +/- 0.10, P < .01) and obese (1.23 +/- 0.18 v 1.03 +/- 0.09
mmol/m2/min, P < .01) subjects. ANOVA indicated that the effects of obesity and
androgenicity are independent and additive. In both lean and obese PCO women, treatment
with flutamide for 1 or 3 months markedly improved the clinical and biochemical androgenic
features, but did not significantly influence the overall insulin sensitivity. A large
disparity between individuals in the response to treatment correlated significantly with a
simultaneous reduction in plasma levels of dehydroepiandrosterone sulfate (DHEA-S). Thus
in women, PCO and obesity exert synergistic effects on insulin resistance. The decreased
insulin sensitivity is mediated via indirect androgenic actions or nonandrogenic
mechanisms. In some individuals, a direct effect of androgens might have been masked by a
decrease in DHEA-S levels.
Language of Publication
English
Unique Identifier
95240459
content2 |
|
